Progress and prospects of early detection in lung cancer

By S. Blandin Knight, P. Crosbie, H. Balata, Jakub Chudziak, T. Hussell, C. Dive. Open Biology, 2017

814 citations recorded by the source corpus.

Lung cancer is the leading cause of cancer-related death in the world. It is broadly divided into small cell (SCLC, approx. 15% cases) and non-small cell lung cancer (NSCLC, approx. 85% cases). The main histological subtypes of NSCLC are adenocarcinoma and squamous cell carcinoma, with the presence of specific DNA mutations allowing further molecular stratification. If identified at an early stage, surgical resection of NSCLC offers a favourable prognosis, with published case series reporting 5-year survival rates of up to 70% for small, localized tumours (stage I). However, most patients (approx. 75%) have advanced disease at the time of diagnosis (stage III/IV) and despite significant developments in the oncological management of late stage lung cancer over recent years, survival remains poor. In 2014, the UK Office for National Statistics reported that patients diagnosed with distant metastatic disease (stage IV) had a 1-year survival rate of just 15–19% compared with 81–85% for stage I.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/1c7d7990c592c23658c8af01bdd8b5c2c38d7c73

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Citations in the corpus

Current and Future Development in Lung Cancer Diagnosis (2021, background): “In addition, lung cancer is commonly resistant to standard therapeutic modalities such as chemotherapy and radiation, which together with the lack of successful treatment for metastatic disease, adds to the dismal outcome [8].”